Literature DB >> 19211652

The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis.

Gowrie Balasubramaniam1, Edwina A Brown, Andrew Davenport, Hugh Cairns, Barbara Cooper, Stanley L S Fan, Ken Farrington, Hugh Gallagher, Patrick Harnett, Sally Krausze, Simon Steddon.   

Abstract

BACKGROUND: Encapsulating peritoneal sclerosis (EPS) is a disease process that can occur as a complication of peritoneal dialysis (PD). The aim of this study was to make a general assessment of the clinical features, diagnosis, management and outcome of PD-related EPS cases from London and South-East England.
METHODS: Questionnaires were sent to 11 PD units in March 2007; cases were identified retrospectively. Outcome data on surviving patients were collected in March 2008.
RESULTS: A total of 111 patients were identified; the mean time on PD was 82 months (range 8-247). Mortality increased with length of time on PD, being 42% at <3 years (n = 12), 32% at 3-4 years (n = 19), 61% at 5-6 years (n = 31), 54% at 7-8 years (n = 24), 75% at 9-10 years (n = 8) and 59% at >10 years (n = 17). Twelve patients had no previous peritonitis episodes, 28 had one previous episode, 30 had two previous episodes and 33 had three or more previous episodes. Of the patients with PD details available, 41/63 were high (>0.81) transporters and 44/71 had ultrafiltration <1 l/24 h, but 7/63 were low average transporters (0.5-<0.65) and 27/71 had ultrafiltration >1 l/24 h and a few had significant residual renal function. Sixty-five (59%) patients had their PD discontinued prior to diagnosis (51 HD; 14 transplanted). CT scans were performed on 91 patients and laparotomy on 47 patients. Drug treatment consisted of tamoxifen, immunosuppression or both. The median survival was 15 months in patients treated with tamoxifen (n = 17), 12 months in patients treated with immunosuppression (n = 24) and 21 months in patients who received both (n = 13), against 13 months (n = 46) in patients who received no specific treatment. Adhesionolysis was performed in 5 patients, and 39 patients were given parenteral nutrition. The overall mortality was 53% with a median survival of 14 months and a median time to death of 7 months. Conclusion. This is one of the largest cohorts of patients with EPS in the literature. Long-term survival occurred in over 50%, regardless of the various treatments strategies undertaken by the centres.

Entities:  

Mesh:

Year:  2009        PMID: 19211652     DOI: 10.1093/ndt/gfp008

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  45 in total

Review 1.  Encapsulating peritoneal sclerosis: a single-center experience and review of the literature.

Authors:  Konstantina Trigka; Periklis Dousdampanis; Maggie Chu; Saimah Khan; Mufazzal Ahmad; Joanne M Bargman; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2010-10-06       Impact factor: 2.370

2.  The Role of NGAL in Peritoneal Dialysis Effluent in Early Diagnosis of Peritonitis: Case-Control Study in Peritoneal Dialysis Patients.

Authors:  Francesca Martino; Elisa Scalzotto; Davide Giavarina; Maria Pia Rodighiero; Carlo Crepaldi; Sonya Day; Claudio Ronco
Journal:  Perit Dial Int       Date:  2014-11-13       Impact factor: 1.756

3.  Towards standardized reporting in studies of encapsulating peritoneal sclerosis.

Authors:  Mark Lambie; Niko Braun; Simon J Davies
Journal:  Perit Dial Int       Date:  2013 Sep-Oct       Impact factor: 1.756

Review 4.  Encapsulating peritoneal sclerosis in children.

Authors:  Constantinos J Stefanidis; Rukshana Shroff
Journal:  Pediatr Nephrol       Date:  2013-11-21       Impact factor: 3.714

Review 5.  Increasing the use of biocompatible, glucose-free peritoneal dialysis solutions.

Authors:  Ahad Qayyum; Elizabeth Ley Oei; Klara Paudel; Stanley L Fan
Journal:  World J Nephrol       Date:  2015-02-06

Review 6.  Encapsulating peritoneal sclerosis.

Authors:  Christopher J Danford; Steven C Lin; Martin P Smith; Jacqueline L Wolf
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

7.  Fibrosing pericarditis in a patient with encapsulating peritoneal sclerosis.

Authors:  L Tonneijck; S Florquin; M R Korte; N H Schut
Journal:  Perit Dial Int       Date:  2012 Nov-Dec       Impact factor: 1.756

Review 8.  Encapsulating peritoneal sclerosis: the state of affairs.

Authors:  Mario R Korte; Denise E Sampimon; Michiel G H Betjes; Raymond T Krediet
Journal:  Nat Rev Nephrol       Date:  2011-08-02       Impact factor: 28.314

9.  Can EPS development be avoided with early interventions? The potential role of tamoxifen--a single-center study.

Authors:  Erika De Sousa-Amorim; Gloria Del Peso; M Auxiliadora Bajo; Laura Alvarez; Marta Ossorio; Fernando Gil; Teresa Bellon; Rafael Selgas
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

10.  Sclerosing encapsulating peritonitis after living donor liver transplantation: a case successfully treated with tamoxifen: report of a case.

Authors:  Takayuki Takeichi; Yasuko Narita; Kwang-Jong Lee; Hidekazu Yamamoto; Katsuhiro Asonuma; Yukihiro Inomata
Journal:  Surg Today       Date:  2012-10-26       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.